“…[ 15 ] Most currently available sonosensitizers are developed from conventional photosensitizers, including organic dyes (e.g., methylene blue, indocyanine green, acridine orange), [ 16–18 ] porphyrin‐derivatives (e.g., photofrin, hematoporphyrin, protoporphyrin IX, [ 19–21 ] and inorganic nanoparticles (e.g., silicon‐based nanoparticles, metal nanoparticles). [ 22–25 ] Yet, only limited SDT trials have entered the early preclinical phases owing to the inadequacies of the extant sonosensitizers in the ROS production, stability under sono‐irradiation, and biocompatibility, thus conferring modest therapeutic efficacy. Therefore, it is highly demanded to develop effective sonosensitizers with stable and sufficient ROS production for in vivo therapeutic applications.…”